中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 6
Jun.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(6): 1280-1287

Effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure: An analysis based on high-throughput sequencing

DOI: 10.3969/j.issn.1001-5256.2022.06.013

  • Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding:

"Capital Featured Clinical Application Research Projects" of Beijing Science and Technology Committee (Z181100001718052);

Green Seed Plan of Beijing Hospitals Authority (QMl220201802);

Fund for Beijing Science & Technology Development of TCM (Qn-2020-25);

Pilot Project of Clinical Cooperation Between Traditional Chinese Medicine and Western Medicine for Major and Difficult Diseases, State Administration of Traditional Chinese Medicine (2018-6-4);

Regional Traditional Chinese Medicine Diagnosis and Treatment Center, State Administration of Traditional Chinese Medicine (2019-3-18)

More Information
  • Corresponding author: WANG Xianbo, wangxianbo638@163.com (ORCID:0000-0002-3593-5741)
  • Received Date: 2021-06-04
  • Accepted Date: 2021-07-08
  • Published Date: 2022-06-20
    Abstract
  •   Objective  To investigate the effect of Liangxue Jiedu decoction on intestinal flora in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).  Methods  The patients who were hospitalized and diagnosed with HBV-ACLF in Beijing Ditan Hospital from October 2018 to October 2019 were enrolled, and healthy individuals were enrolled as HP group. High-throughput sequencing was used to screen for the differences in bacterial diversity and species between HBV-ACLF patients and healthy individuals, and differentially expressed bacteria between the two groups were screened out at the phylum and genus levels. With the help of in vitro simulated fermentation experiment, fecal samples were collected from the patients with HBV-ACLF and were then cultured in the medium containing different concentrations of Liangxue Jiedu decoction (0, 10%, 50%, and 100%) for 24 hours, and the changes in intestinal flora were analyzed and compared between the HBV-ACLF treatment group, the HBV-ACLF non-treatment group, and the HP group at the genus level. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups.  Results  A total of 10 HBV-ACLF patients were enrolled, with 5 in the HBV-ACLF treatment group and 5 in the HBV-ACLF non-treatment group, and there were 15 individuals in the HP group. Compared with the HP group, the HBV-ACLF non-treatment group had significant reductions in the diversity and abundance of intestinal flora. At the phylum level, Bacteroidetes and Firmicutes were mainly observed in the samples of the HP group, while the HBV-ACLF non-treatment group had a significant reduction in Bacteroidetes and significant increases in Fusobacteria, Proteobacteria, and Fibrobacteres. At the genus level, compared with the HP group, the HBV-ACLF non-treatment group had significant reductions in Ruminococcus, Blautia, and Eubacterium and significant increases in Parabacteroides, Lactobacillus, Fusobacterium, and Streptococcus. The in vitro fermentation experiment showed that compared with the HBV-ACLF non-treatment group, the HBV-ACLF treatment group had significant increases in Ruminococcus, Lachnospira, Bacteroides, and Genusgenus and significant reductions in Fusobacterium and Proteobacteria (all P < 0.05).  Conclusion  Liangxue Jiedu decoction can regulate intestinal flora disturbance, restore the diversity of intestinal flora, increase dominant bacteria, and reduce pathogenic bacteria, which may be one of its important mechanisms of action in the treatment of HBV-ACLF.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
    [2]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [3]
    ALAM A, CHUN SUEN K, MA D. Acute-on-chronic liver failure: Recent update[J]. J Biomed Res, 2017, 31(3): 1-18. DOI: 10.7555/JBR.31.20160060.
    [4]
    ZHANG HL, YU LX, YANG W, et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J]. J Hepatol, 2012, 57(4): 803-812. DOI: 10.1016/j.jhep.2012.06.011.
    [5]
    ARULRAJ R, NEUBERGER J. Liver transplantation: Filling the gap between supply and demand[J]. Clin Med (Lond), 2011, 11(2): 194-198. DOI: 10.7861/clinmedicine.11-2-194.
    [6]
    SOL C, GUILLY S, DA SILVA K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative met- agenomics: Relationship with acute - on - chronic liver failure and prognosis[J]. Gastroenterology, 2021, 160(1): 206-218. e13. DOI: 10.1053/j.gastro.2020.08.054.
    [7]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure[J]. Inter J Epidemiol Infect Dis, 2013, 40(1): 1-7. DOI: 10.3760/cma.j.issn.1673-4149.2013.01.001.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 国际流行病学传染病学杂志, 2013, 40(1): 1-7. DOI: 10.3760/cma.j.issn.1673-4149.2013.01.001.
    [8]
    LIAO W, TANG Y, FAN WH, et al. Analysis of intestinal flora imbalance and its influencing factors in patients with acute-on-chronic liver failure[J]. Traum Crit Med, 2021, 9(5): 394-396. DOI: 10.16048/j.issn.2095-5561.2021.05.17.

    廖威, 唐艳, 范文瀚, 等. 慢加急性肝衰竭患者肠道菌群失调情况及影响因素分析[J]. 创伤与急危重病医学, 2021, 9(5): 394-396. DOI: 10.16048/j.issn.2095-5561.2021.05.17.
    [9]
    DALAL R, MCGEE RG, RIORDAN SM, et al. Probiotics for people with hepatic encephalopathy[J]. Cochrane Database Syst Rev, 2017, 2(2): CD008716. DOI: 10.1002/14651858.CD008716.pub3.
    [10]
    ALDAD A, MORENO RG, SHIBAYAYANA M, et al. Protective effects of allopurinol against acute liver damageand cirrhosis induced by carbon tetrachloride: Modulation of NF-κB, cytokine production and oxidative stress[J]. Biochim Biophys Acta, 2012, 1820(2): 65-75.
    [11]
    LOUIS P, YOUNG P, HOLTROP G, et al. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA: Acetate CoA-transferase gene[J]. Environ Microbiol, 2010, 12(2): 304-314. DOI: 10.1111/j.1462-2920.2009.02066.x.
    [12]
    MOOKERJEE RP, PAVESI M, THOMSEN KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure[J]. J Hepatol, 2016, 64(3): 574-582. DOI: 10.1016/j.jhep.2015.10.018.
    [13]
    WOODHOUSE CA, PATEL VC, SINGANAYAGAM A, et al. Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharmacol Ther, 2018, 47(2): 192-202. DOI: 10.1111/apt.14397.
    [14]
    XIE G, ZHONG W, LI H, et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption[J]. FASEB J, 2013, 27(9): 3583-3593. DOI: 10.1096/fj.13-231860.
    [15]
    TELTSCHIK Z, WIEST R, BEISNER J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J]. Hepatology, 2012, 55(4): 1154-1163. DOI: 10.1002/hep.24789.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (497) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return